GLP-1 Companion Protocol: Compounded Glutathione SubQ Injections
Supporting Phase II hepatic conjugation, eliminating sluggish detox fatigue, and protecting lean mass
Why Should Patients on Semaglutide or Tirzepatide Take Glutathione Injections?
When GLP-1 agonists trigger rapid lipolysis, stored lipophilic environmental toxins and oxidized free radicals flood the bloodstream, depleting liver glutathione stores and causing post-dose sluggishness. Subcutaneous Glutathione injections restore Phase II liver clearance, reducing metabolic fatigue and protecting hepatocytes. Doctor-prescribed under Section 503A, subcutaneous GSH conjugates directly with reactive electrophilic metabolites, converting toxic lipophilic compounds into water-soluble mercapturic acids for safe renal and biliary excretion.
The Biology of Rapid Lipolysis: Mobilizing Stored Adipose Toxins
In our clinical monitoring of patients using Compounded Semaglutide and Compounded Tirzepatide, weight loss typically averages 15 to 25% of baseline body mass. However, rapid fat loss places immense oxidative strain on hepatic micro-circulation.
Adding weekly subcutaneous micro-injections of medical-grade Glutathione provides the critical sulfur-bearing substrate required to bind mobilized metabolites. Explore prescription details on our primary 503A compounded Glutathione program page.
Phase I vs. Phase II Hepatic Detoxification During Weight Loss
The human liver detoxifies compounds in two distinct steps:
- Phase I Functionalization: Cytochrome P450 enzymes break down complex lipids, often generating intermediate metabolites that are significantly more reactive and damaging than the initial compound.
- Phase II Conjugation: Glutathione S-transferase attaches a glutathione molecule to this reactive intermediate, rendering it completely inert and water-soluble for excretion.
If a patient's intracellular glutathione is depleted due to caloric restriction, Phase I intermediates accumulate, producing systemic oxidative stress, head tension, and low energy. Injectable SubQ Glutathione keeps Phase II clearance running at peak capacity.
Expert Clinical Take:
“Patients often blame GLP-1 medications for fatigue, when in reality their liver is struggling to neutralize the surge of lipid peroxides released during visceral fat catabolism. Co-administering subcutaneous glutathione twice weekly eliminates this bottleneck, revitalizing liver function and clearing the brain fog commonly associated with aggressive calorie deficits.”